Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults

OBJECTIVES: We aimed to evaluate the safety and optimal dose of a novel inactivated whole-virus adjuvanted vaccine against SARS-CoV-2: VLA2001. METHODS: We conducted an open-label, dose-escalation study followed by a double-blind randomized trial using low, medium and high doses of VLA2001 (1:1:1)....

Descripción completa

Detalles Bibliográficos
Autores principales: Lazarus, Rajeka, Taucher, Christian, Brown, Claire, Čorbic Ramljak, Irena, Danon, Leon, Dubischar, Katrin, Duncan, Christopher J.A., Eder-Lingelbach, Susanne, Faust, Saul N., Green, Christopher, Gokani, Karishma, Hochreiter, Romana, Wright, Johanna Kellett, Kwon, Dowan, Middleditch, Alexander, Munro, Alasdair P.S., Naker, Kush, Penciu, Florentina, Price, David, Querton, Benedicte, Riaz, Tawassal, Ross-Russell, Amy, Sanchez-Gonzalez, Amada, Wardle, Hayley, Warren, Sarah, Finn, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd on behalf of The British Infection Association. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212764/
https://www.ncbi.nlm.nih.gov/pubmed/35718205
http://dx.doi.org/10.1016/j.jinf.2022.06.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212764/
https://www.ncbi.nlm.nih.gov/pubmed/35718205
http://dx.doi.org/10.1016/j.jinf.2022.06.009

Ejemplares similares